Altergon

Altergon Italia is the Italian production and R&D arm of the Swiss company Altergon SA, established in 2001 in the industrial area of Morra de Sanctis (Avellino), in the Campania region of southern Italy. The company was created after the commercial success of products licensed by Altergon SA to multinational pharmaceutical firms, a success that led the Swiss parent to build a dedicated manufacturing and research operation on Italian soil. Today Altergon Italia presents itself as a Centre of Excellence and Innovation for the production of medicated patches and for the biotechnological manufacture of ultra-pure hyaluronic acid. The company operates as a Contract Development and Manufacturing Organization (CDMO), offering clients modern drug-delivery systems rather than only finished consumer brands. Its portfolio of products and services includes the formulation and production of medicated patches and transdermal patches (Drug in Adhesive), hydrogel medicated patches, orodispersible films (ODF), biotechnological production of ultra-pure hyaluronic acid with customisable molecular weight, viscosity and packaging, pre-filled sterile syringes (PFS), medical devices, microneedles, impregnated gauze, secondary packaging and pharmaceutical warehousing, quality-control analysis and QP release certification. It also provides formulation studies, process-validation batches, pilot batches including for clinical trials, process and analytical-method validation, testing on primary and secondary packaging materials, and batch release of raw materials and finished products. Altergon Italia describes its strength as combining strict compliance with the rules and ethical principles governing pharmaceutical production with a strong focus on innovation and scientific research. Its production, packaging and R&D activities are supported by modern high technology and highly qualified technical staff. The company states that the uniqueness of its processes allows it to identify itself as a European leader in the production of hydrogel medicated patches, Drug in Adhesive patches and edible films for systemic release (ODF). The manufacturing site occupies roughly 50,000 square metres in the ASI industrial nucleus of Morra de Sanctis. Of this, about 20,000 square metres are dedicated to production departments and warehouses, 1,000 square metres to technical and management offices, 10,000 square metres to external technical areas and services, 4,000 square metres to equipped green areas, and 15,000 square metres are reserved for future expansion. The site currently comprises four production facilities, three R&D laboratories (800 square metres) and two pilot plants, one biotech (350 square metres) and one for patches. Altergon Italia markets its own hyaluronic acid expertise under the Shyalt brand, described as an ultrapure hyaluronic acid developed in the company's R&D laboratories and positioned as a new frontier in hyaluronic acid. The company is privately held within the Altergon group and does not trade on a public stock exchange. Its business model is largely business-to-business, serving pharmaceutical and medical-industry clients who need specialised drug-delivery platforms and contract manufacturing capacity.

Altergon Italia was founded in 2001 as the Italian production and R&D operation of the Swiss company Altergon SA. According to the company's own account, the decision to establish a manufacturing and research presence in Italy followed the success of certain products that Altergon SA had licensed to multinational companies in the pharmaceutical sector. The new Italian entity was set up to build on that commercial momentum with dedicated industrial capacity and scientific research. The company chose the ASI industrial nucleus of Morra de Sanctis, in the province of Avellino (Campania), as the location for its production site. Over time the site grew into a complex of four production facilities, three R&D laboratories covering about 800 square metres, and two pilot plants — one biotech of about 350 square metres and one for patches. The total area is approximately 50,000 square metres, with about 20,000 square metres dedicated to production departments and warehouses, 1,000 square metres of technical and management offices, 10,000 square metres of external technical areas and services, 4,000 square metres of equipped green areas, and 15,000 square metres reserved for future expansion. From the outset, Altergon Italia focused on medicated patches as its core business. It developed proprietary processes for hydrogel medicated patches, Drug in Adhesive transdermal patches and edible films for systemic release (ODF), and states that the uniqueness of these processes allows it to identify itself as a European leader in these categories. Alongside patch technology, the company built a biotechnological capability for the production of ultra-pure hyaluronic acid, marketed under the Shyalt brand and described as an ultrapure hyaluronic acid developed in its R&D laboratories. As it matured, Altergon Italia positioned itself not only as a manufacturer of its own technologies but as a Contract Development and Manufacturing Organization (CDMO) serving pharmaceutical and medical-industry clients. Its service offering expanded to include formulation and production of medicated patches and transdermal patches, hydrogel patches, ODF, ultra-pure hyaluronic acid with customisable molecular weight, viscosity and packaging, pre-filled sterile syringes, medical devices, microneedles and impregnated gauze. It also added secondary packaging and pharmaceutical warehousing, quality-control analysis and QP release certification, formulation studies, process-validation batches, pilot batches including for clinical trials, process and analytical-method validation, and testing on primary and secondary packaging materials. The company emphasises that its strength lies in combining strict compliance with the rules and ethical principles regulating pharmaceutical production with attention to innovation and scientific research. Its production, packaging and R&D processes are supported by modern high technology and highly qualified technical and professional staff. Altergon Italia remains a privately held part of the Altergon group, with its parent Altergon SA based in Switzerland, and continues to operate its integrated site at Morra de Sanctis.

• 2001

  Altergon SA establishes Altergon Italia as a production and R&D operation in Italy following the success of products licensed to multinational pharmaceutical companies.

• Altergon Italia develops proprietary processes for hydrogel medicated patches, Drug in Adhesive transdermal patches and orodispersible films (ODF), positioning itself as a European leader in these categories.

• The company builds biotechnological capability for ultra-pure hyaluronic acid and markets it under the Shyalt brand.

• Altergon Italia expands its Morra de Sanctis site to four production facilities, three R&D laboratories and two pilot plants.

European leader in hydrogel medicated patches and transdermal Drug in Adhesive patches; a Centre of Excellence and Innovation and CDMO for advanced drug-delivery systems.

• Medicated patches (hydrogel)

  Hydrogel medicated patches formulated and produced by Altergon Italia, described as a core business and a category where the company identifies itself as a European leader.

• Transdermal patches (Drug in Adhesive)

  Drug in Adhesive transdermal patches for controlled delivery of active substances through the skin.

• Orodispersible films (ODF)

  Edible films for systemic release, produced as part of Altergon's drug-delivery portfolio.

• Shyalt ultrapure hyaluronic acid

  Ultrapure hyaluronic acid developed in Altergon Italia's R&D laboratories, with customisable molecular weight, viscosity and packaging.

• Pre-filled sterile syringes (PFS)

  Sterile pre-filled syringes produced as part of the company's manufacturing services.

• Microneedles

  Microneedle technology for transdermal administration of active substances.

• Impregnated gauze

  Impregnated gauze produced as part of the company's medical product range.

1. 1Altergon Italia | Leading Pharmaceutical Innovationaltergon.it
2. 2Leading Pharmaceutical Innovation - Altergonaltergon.it
3. 3Una moderna CDMO per l’innovazione dei prodotti e la qualità per i nostri clienti - Altergonaltergon.it
4. 4Altergon - Wikidatawikidata.org